Cidofovir, a nucleoside analog of deoxycytidine monophosphate, is a water-soluble polar molecule that exhibits antiviral activity against a broad range of DNA viruses. Cidofovir for injection is approved for the treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. The safety and efficacy of topical cidofovir has been described in a limited number of patients. We present two cases of multidrug-resistant herpes simplex virus infections that responded to topical cidofovir therapy yet resulted in irreversible acute kidney injury.
NaranjoCABustoUSellersEM. A method for estimating probability of adverse drug reactions. Clin Pharmacol Ther1981; 30: 239–245.
4.
TanHHGohCL. Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies. Am J Clin Dermatol2006; 7: 13–29.
5.
EvansKGMorrisseyKAGoldsteinSC. Chronic acyclovir-resistant HSV-2 ulcer in an immunosuppressed patient treated with topical cidofovir. Arch Dermatol2011; 147: 1462–1463.
6.
SellarRSPeggsKS. Management of multidrug-resistant viruses in the immunocompromised host. Br J Haematol2012; 156: 559–572.
7.
ChakrabartiSPillayDRatcliffeD. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. J Infect Dis2000; 181: 2055–2058.
8.
BaconTHLevinMJLearyJJ. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev2003; 16: 114–128.
9.
TomblynMChillerTEinseleH. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Biol Blood Marrow Transplant2009; 15: 1143–1238.
10.
LalezariJSchackerTFeinbergJ. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Di1997; 176: 892–898.
11.
LateefFDonPCKaufmannM. Treatment of acyclovir-resistant, foscarnet-unresponsive HSV infection with topical cidofovir in a child with AIDS. Arch Dermatol1998; 134: 1169–1170.
12.
SimsCRThompsonKChemalyRF. Oral topical cidofovir: novel route of drug delivery in a severely immunosuppressed patient with refractory multidrug-resistant herpes simplex virus infection. Transpl Infect Dis2007; 9: 256–259.
13.
MulunehBDeanAArmisteadPA. Successful clearance of cutaneous acyclovir-resistant, foscarnet-refractory herpes virus lesions with topical cidofovir in an allogeneic hematopoietic stem cell transplant patient. J Oncol Pharm Prac2012; 0: 1–5.
14.
BienvenuBMartinezFDevergieA. Topical use of cidofovir induced acute renal failure. Transplantation2002; 73: 661–662.
15.
CundyKCLynchGLeeWA. Bioavailability and metabolism of cidofovir following topical administration to rabbits. Antiviral Res1997; 35: 113–122.
